Skip to main content

EpimAb Bio Starts Clinical Trials of Two Bispecific Candidates

EpimAb Biotherapeutics, a Shanghai-Suzhou company, started clinical trials of two bispecific antibodies. The company dosed the first patient in a Phase I/II trial of EMB-02, which targets PD-1 and LAG-3, in patients with advanced solid tumors; it also began a Phase I/II trial of EMB-06, a bispecific antibody targeting BCMA and CD3, in recurrent and refractory multiple myeloma. The EMB-02 trial is taking place in the US and Australia , while the EMB-06 trial is being conducted in Australia . More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.